Visited Librarian for Second Research Deliverable
Date of visit
Name of librarian
Signature of librarian
Student name
Key outcomes (in bullet form
is sufficient)
Research (2) Rubric
Evaluation Area
1. Selection of sources
(15%)
•
•
2. Breadth of Research
(includes both
primary and
secondary research)
(60%)
Percentage relates to
the total points
available for this
section
3. Depth of research
(includes both
primary and
secondary research)
(25%)
4. Citations
5%
Exceeds Expectations
Identified highly appropriate sources in a
variety of formats (books, journals,
electronic sources)
•
Meets Expectations
Identified mostly appropriate sources in a
variety of formats (books, journals,
electronic sources)
•
Below Expectations
Little attempt to balance
formats (books, journals,
electronic sources)
Leveraged librarian to fully take advantage
of the library databases for research
•
Used one source from the librarian’s talk
•
Over-reliance on the internet
•
Visited the librarian and got some value to
deepen the research.
•
Did not visit the librarian.
Expansive research
8 sources 93%
9+ 95+%
Primary research an integral part of findings.
•
•
•
•
Sufficient research
6 sources 83%
7 sources 88%
Primary Research included and is of value
•
•
Insufficient research
under 3 or less sources 0 for
this section
4 sources 75%
5 sources 80%
Primary Research not included
• Showed creativity in approaching the
research enabling expansion or deepening
of the research question
• Research was very specific to the question
and the gaps
• Identified gaps where further research is
required
• Wrote notes including succinct key facts
which directly answered all of the research
questions
•
Were able to adapt the research question
to answer the research question
adequately
Research was somewhat specific to the
question and gaps
Some gaps were identified
Wrote notes which included facts that
answered most of the research questions
and were written in the student’s own
words.
•
•
•
Cited most sources of information in APA
format and documented sources to enable
accuracy checking.
Organized per column one with key
findings mostly in depth
•
•
•
•
•
Cited all sources of information accurately
in APA format to demonstrate the
credibility and authority of the information
presented and for use for the
presentation/report.
• Organized using date, source (or name of
interviewer, key findings in depth, category,
clear identification of gaps)
Grade % /125
•
•
•
•
•
•
•
•
•
•
•
Research question was
answered somewhat
Research was random or
insufficiently tied to the
question/gaps
No gaps were identified
Wrote notes which included
irrelevant facts which did not
answer the research
questions.
Cited most sources of
information improperly and
provided little or no supporting
documentation to check
accuracy.
Information not organized
** note: everyone should visit the librarian to better leverage the library databases. You may do this individually or with other members of your team. The only exception is if you are solely
responsible for the primary research for your group.
Research Deliverable (2)
Objective: To answer the client question with in depth research that challenges the
researcher to look at the question from a variety of angles. To ensure breadth and depth of
research.
Format: Use the same format as research deliverable (1). Spelling, grammar, etc. are not
graded. Please include your key findings organized as follows
1. List your team objective/overall question
2. List your specific tasks assigned for this deliverable
3. Describe your research with the following information (or use the secondary
research notes document outline)
o Date of research
o List the gaps you identified in your first research deliverable and
explain the research you found for these gaps.
o The key findings by source in 2 - 3 sentences or bullets
o Sources of information utilized in APA format. Include link if found
online.
o Include the key findings from your first research deliverable in 3-5
sentences or bullets
4. List the areas that you will not cover. This will be used in case the client asks
a question in this area
5. Clearly identify/differentiate the research from your second
deliverable.
Details:
Please summarize your key findings succinctly. What did you find in your research? What
information did it give you? What is missing? Your findings should be thorough enough
that I can clearly understand what you learned as well as useful enough that you can easily
use them directly for your analysis/presentation preparation.
Although volume of research was emphasized for the first deliverable, quality is more
important here. You still need a quantity of research but this deliverable should be more
focused on what you need specifically to draw conclusions.
The second deliverable should address your gaps as well as any other additional
information you found.
Do not list a bibliography. Match the findings with the citation so that it is clear what you
found where.
Sample Student
MGT 419 – Second Research Deliverable
Due: ****
Research Question:
What is the size and nature of the large pharmaceuticals market here (e.g. how many companies are here and what research or business operations are
taking place locally)? Which aspects of drug discovery are they current outsourcing and to where? What criteria do they use to determine what to
outsource? What are their needs? What other areas are they considering outsourcing? Which aspects of international outsourcing are they currently
uncomfortable with (e.g. potential opportunities for reverse sourcing)? Where can Large Biotech- add value? How might they take more of this
outsourcing market? What’s the potential/opportunity?
Research Categories:
Competitors
Customers
• Pharma
• Biotech
International
Industry
• Pharma
• Biotech
Outsourcing
Regulatory
Not relevant to our question
Categories Assigned:
My research is predominately focused on market analysis and business opportunities in the area. These fall under the research categories of industry
(pharma/biotech) and customers (pharma/biotech).
Secondary Research Notes:
Research Category: Customers –pharma/biotech
Date of Research: ****
Summary of Research: I did a scrub of LinkedIn profiles in an attempt to set up research interviews. I searched for people who worked for different
pharma/biotech companies that had “outsourcing” or “procurement” in their job titles.
Key Findings:
• Most of the people who met my criteria worked in overseas operations for the firms. This supports the statement that Mike Earley made
during our last client meeting – that the big pharma companies house their compounds overseas where they have more warehouse space and
ship compounds to their U.S. labs on an as needed basis.
Missing Information/Additional Questions:
• Come up with a comprehensive list of names/titles/organizations for Large Biotech. This will help them identify contacts at these companies
for business development.
• Identify people who are part of the “compound management” group on LI.
Citation and URL: Valastyan, L. (2011, April 12). Sample management sig. Retrieved from
http://www.linkedin.com/groups?gid=3867638&trk=skills
Page 1 of 8
Sample Student
MGT 419 – Second Research Deliverable
Due: ****
Research Category: Customers; Industry
Date of Research: ****
Summary of Research: This article discusses a survey that was published on pharmaceutical compound management that looked at the current
business practices, issues and trends. The survey had a specific focus on quality control.
Key Findings:
• Main issue in compound management = sample integrity
• Biggest bottleneck =retrieval of compounds and capacity
• Mean size of a compound library was expected to be 1.8M in large pharma and 1.25M for small pharma by 2008.
• CM facilities place a huge importance on sample integrity – specifically, the degree to which the structure of the compound is what it’s
supposed to be as labeled; the purity of the sample; and, the concentration of the sample. Water uptake is the main reason sample integrity is
compromised. As such, quality control measures to assess the integrity of samples is a major priority for CM facilities.
• Retrieval rates in automated CM is important because it’ll determine how quickly a company will receive their samples. This is based on the
size of the order, whether items are retrieved as entire racks or are individually cherry-picked, the number of times on a tray and whether
alternative vessels are available for use. Additionally, items that are retrieved frequently are easier to find.
• Flexibility is important in order to develop new routes to integrate into the process. Non-invasive technologies that monitor samples and life
cycles are important. Also, increasing the size of the collection to be more diverse and targeted to specific disease-states with faster turnaround
times.
Missing Information/Additional Questions:
• Updated numbers??
Citation and URL: Comley, J. (2005). Compound management in pursuit of sample integrity.. Retrieved from http://www.ddwonline.com/enabling-technologies/p148346-compound-management-in-pursuit-of-sample-integrityspring-05.html
Research Category: Customers; Large Biotech; Outsourcing
Date of Research: ****
Summary of Research: This book discusses the key features of compound management facilities, IT infrastructure supporting CM facilities and the
reasons for outsourcing sample management.
Key Findings:
KEY FEATURES OF CM IT SYSTEMS:
• CM IT systems must have inventory features; track receipt; creation; movement; and, dispatch of samples. The more advance systems also
provide processes that guide the sample manager through a workflow when fulfilling requests.
• The system must have an inventory view and order management components.
• Databases recognize labware based on barcodes which will tell the sample manager the type of the compound, amount stored and location of the
item.
• Sample manager must have a means of importing and editing inventory items.
• Dispatch operations tell the sample manager where the item has been dispatched to and updates the system with the new location. It could also
Page 2 of 8
Sample Student
•
MGT 419 – Second Research Deliverable
Due: ****
feature automated receipt systems that send a delivery note to recipients.
Reports and metrics related to process throughput, current stock and restock items, turnaround time and machine utilization.
OUTSOURCING
• Total pharma biotech and outsource market is estimated at $33B and is expected to reach $48B. R&D outsourcing is approximately 50% of the
total market.
• Main benefits of outsourcing are economic and organizational; outsourcing provides access to technology and capacity without the need for
investment in equipment or personnel. It also offers flexibility. It provides access to the latest technology and capacity while avoiding capitcal
investment and reducing depreciation costs.
• Companies who choose to outsource must consider their own resources, how the vendor will provide cost savings, physical resources and
human resources.
• Successful outsourcing provides cost savings, increased operational efficiency, and optimization or resource allocation.
• Outsourcing is about building LT relationships with the vendor built on quality, service, knowledge, culture and cost.
• Outsourcing entire compound management activities to a third-party is rare for major pharma companies. However, M&A reorganization
usually means that compound collections need to be moved between sites or brought together into a single collection, so using a third-party,
neutral, outsourcing path may help prevent internal management conflicts.
KEY COMPETENCIES FOR CM VENDORS:
• Privacy protection for samples
• Robust chain of custody procedures for samples
• Appropriate conditions for sample storage
• Procedures to comply with regulations
• Sample coding
Missing Information/Additional Questions:
Citation and URL: Wigglesworth, M., & Wood, T. (****). Management of chemical and biological samples for screening applications. (pp. 265-272,
367-378). Germany: John Wiley & Sons. Retrieved from http://books.google.com/books?id=Hd6HRB4AWf8C&pg=PA379&lpg=PA379&dq=sample
library
pharma&source=bl&ots=GVyvZp3JuZ&sig=9h2XXJJRPgQt2plmn7CDhVWX8jY&hl=en&sa=X&ei=F0SgUPafELGw0AH0yYFY&ved=0CFcQ6AEwBTg
K
http://books.google.com/books?id=Hd6HRB4AWf8C&pg=PA265&dq=sample+library+pharma&source=gbs_toc_r&cad=4#v=onepage&q&f=false
Related interview - http://www.slideshare.net/PharmaIQ/correct-compound-man-report-pdf
Page 3 of 8
Sample Student
MGT 419 – Second Research Deliverable
Due: ****
Research Category: Industry – Pharma/Biotech
Date of Research: ****
Summary of Research: This article discusses the safety and efficacy of biosimilar molecules that are used to develop generic versions of drugs. The
small molecules that are being copied to create these biosimilars are not precise because they’re being made from human/animal agents rather than
chemical agents.
Key Findings:
• There is a huge area of quality control that Large Biotech needs to focus on in the bioactive molecule segment.
• Slight variations in biosimilar molecules are a huge concern because they could essentially change the way the drug works.
• This is an opportunity for Large Biotech to increase the testing they do on biosimilar agents in order to make it as a close of a match as
possible to the target molecule, which would position Large Biotech as an industry leader in this arena.
• This is directly related to Large Biotech’s core competency areas.
Missing Information/Additional Questions:
Citation and URL: Rosenthal, M. (****, February 1). Clinicians concerned about safety, efficacy of biosimilar drugs. Modern Medicine, Retrieved
from http://www.modernmedicine.com/modernmedicine/article/articleDetail.jsp?id=757558&pageID=1&sk=&date=
Research Category: Industry – Pharma/Biotech, Regulatory Date of Research: ****
Summary of Research: As a result of the Patient Protection and Affordable Care Act, the FDA has placed restrictions on biosimilar agents and
generic drug development. This is an area that impacts Large Biotech’s client base.
Key Findings:
• There are much stronger regulations on biosimilars as a result of the ACA. Large Biotech may have an opportunity to open up the pipeline to
companies who specialize in developing biosimilar drugs.
•
Large Biotech could partner with the companies to create the biosimilar agents by offering their compound management solutions at a
discounted rate. Additionally, they could offer testing services in order to speed up the drug discovery timeline.
Missing Information/Additional Questions:
Citation and URL: Edlin, M. (2011, August 15). Approval pathway for biosimilars still evolving. Drug Topics, 155(8), Retrieved from
http://drugtopics.modernmedicine.com/drugtopics/article/articleDetail.jsp?id=735328
Page 4 of 8
Sample Student
MGT 419 – Second Research Deliverable
Due: ****
Research Category: Customers - Pharma
Date of Research: ****
Summary of Research: Link to Pfizer’s Small Molecule Therapeutics Discovery R&D work. Provides information on current initiatives and
partnership opportunities.
Key Findings:
• Pfizer creates alliances with other companies to advance their R&D work. This is an opportunity for Large Biotech to determine who is
partnering with Pfizer in these areas. Since they already have an agreement with Pfizer’s Boston laboratory, Large Biotech could offer its
services at a discounted price to those organizations in partnership with Pfizer.
•
Pfizer is not looking for a partnership with “compound libraries with no or little track record of finding hits” – could Large Biotech add their
success record to their value proposition to better position them in the market?
Missing Information/Additional Questions:
• Who is currently partnering with Pfizer? http://www.pfizer.com/partnering/partnership_highlights/
Citation and URL: http://www.pfizer.com/partnering/areas_of_interest/small_molecule_therapeutics_discovery.jsp
Research Category: Customers – Pharma
Date of Research: ****
Summary of Research: This press release is regarding the $100M investment AstraZeneca made in 2007 to expand their facility in Waltham, MA.
The second article discusses the new partnership AZ has with the Broad Institute in Cambridge to create a gigantic compound library (over 100,000
compounds) for use in R&D.
Key Findings:
• The MA facility has seen major success in the discovery of drugs to treat three different cancers.
• There has been a decline in the amount of new antibacterial agents that are entering the market. AZ is focused on creating new agents for
worldwide use – could Large Biotech store these on location for them and sell as a middle-man to companies that want to purchase them from
AZ?
• As part of the Broad Institute/AZ partnership, the Broad is testing the drugs in their facility with the hopes of creating drugs that can be used
by patients. Is it more expensive for the Broad to keep these compounds in house?
Missing Information/Additional Questions:
• Does AZ manage their compound inventories in-house? Is the Broad Institute managing all of their compounds? How does the partnership
affect the AZ R&D facility in Waltham?
Citation and URL: http://www.astrazeneca.com/Media/Press-releases/Article/20070122--AstraZeneca-Makes-100M-Research-Investment-InBoston
Page 5 of 8
Sample Student
MGT 419 – Second Research Deliverable
Due: ****
http://www.labtalk.astrazeneca.com/collaboration/the-astrazenecabroad-institute-partnership/
Research Category: Customers - Pharma
Date of Research: ****
Summary of Research: Information on Pfizer’s Groton, CT facility where they house compounds and have a BioBank.
Key Findings:
• For the most part, it appears as though Pfizer does most of their compound management on-site in Groton, CT. They have a Liquid Compound
Management and Distribution center where they are able to fulfill thousands of requests for compounds. However, the client has told us that
they recently secured Pfizer as a client – are they serving just the Boston R&D facility? How can we use their work for Pfizer to secure other
clients who have HQs in other states?
•
Pfizer’s BioBank is cold storage for bioactive molecules. These molecules have very specific environments they need to live in or else they spoil
and are useless. Does Large Biotech have cold storage? They would also need cold storage transport if they were shipping items to local R&D
facilities.
Missing Information/Additional Questions:
Citation and URL: http://www.pfizer.com/research/rd_works/groton_new_london.jsp
Research Category: Customers – Pharma
Date of Research: November 8 , ****
Summary of Research: A press release on the collaboration between AstraZeneca and Pharmacopeia which will shift their focus from compound
libraries to drug discovery to identify small molecule compounds against a specific drug target.
Key Findings:
• Pharmacopeia is providing expertise in identifying small molecule lead compounds for AZ. As part of the partnership, Pharmacopeia is
entitled to receive payment for the successful identification of these compounds. This partnership will help AZ expand its product line and
quality of drugs for specific disease states.
•
The partnership will utilize AZ’s multimillion compound sample library and screening technology.
Missing Information/Additional Questions:
• Many pharma companies create partnerships with smaller firms to expand their R&D and product offerings. This is an opportunity for Large
Biotech to get their foot in the door with big pharma companies by identifying companies that are partners.
Citation and URL: http://www.prnewswire.com/news-releases/pharmacopeia-and-astrazeneca-extend-research-collaboration-74248212.html
Page 6 of 8
Sample Student
MGT 419 – Second Research Deliverable
Due: ****
Research Category: Customers
Date of Research: ****
Summary of Research: Conference hosted on Compound Management. Features names/titles of presenters and sponsors.
Key Findings:
• Company A Institute is based in Needham. This may be an opportunity for Large Biotech to collaborate with CHI to present at their
conferences. May be able to get an attendee list from recent events by calling.
• CHI puts on a ton of events that are right in Large Biotech’s sweet spot.
• By attending these events either as a speaker or a participant, Large Biotech can learn about what their customers want and what their
competitors are doing.
Missing Information/Additional Questions:
• Why doesn’t Large Biotech attend/sponsor these events? If they presented at these conferences, they would gain major visibility with their
target market.
Citation and URL: (2010). The compound management forum, Providence, RI. Retrieved from
http://www.healthtech.com/Conferences_Overview.aspx?id=100928&c=7759
Similar conference – useful for client list:
http://www.compoundmanager.com/Event.aspx?id=665850&utm_source=11314.006PR&utm_medium=11314.006PR&utm_campaign=11314.006PR
&utm_content=10/02/12&mac=11314.006PR
Research Category: Customers – Pharma/Biotech
Date of Research: ****
Summary of Research: This article discusses the wants/needs of Compound and Sample Managers. These are reflective of the wants/needs of
Large Biotech’s clients in the big pharma industry.
Key Findings:
• Access to a large library of HQ compounds and samples and automated technology will enable successful drug discovery.
• Since big pharma companies are handling millions of chemical compounds and samples, the logistics of storing and retrieving the compounds
are more critical than ever.
• High Throughput Screening is becoming a thing of the past and companies are moving to more selective screening processes which conserves
compounds. The process is becoming leaner so libraries need to become more efficient in order to hit the target.
• BioFocus and RTS Group are competitors for Large Biotech.
• PRIMARY CONCERNS FOR Large BiotechMPLE MANAGERS – GRAPH: http://www.pharmaiq.com/images//article_images/large/CM1.jpg
Page 7 of 8
Sample Student
MGT 419 – Second Research Deliverable
Due: ****
Missing Information/Additional Questions:
Citation and URL: Expanding sample libraries tops the wish list for compound and sample managers. (****, May 21). Retrieved from
http://www.pharma-iq.com/pre-clinical-discovery-and-development/articles/expanding-sample-libraries-tops-the-wish-list-for/
Research Category: Customers; Industry
Date of Research: ****
Summary of Research: This journal article discusses the trend of outsourcing compound libraries and assess the value big pharma companies place
on this business decision.
Key Findings:
• Large pharma companies are facing challenges in managing compounds due to M&A. This is because mergers result in compounds being held
various locations with different technologies and non-consolidated databases. The expense of managing more than one library has forced
pharma companies to outsource this function.
• Compound storage is expensive! On top of the capital investments for storage, lab space and equipment, there are also human capital
costs and costs related to technologies. This causes downtime within their preexisting system and impacts other R&D activities.
• Successful CM systems have the following characteristics:
o Easy and accurate accessibility
o Compound integrity
o Efficient usage (less waste!)
o Flexibility to adapt to demand
o Dynamism within the collection
o Availability and integrity of inventory data
• Three main requirements when considering outsourcing inventory:
o Security of the samples
o Robust and reliable IT infrastructure (with firewalls)
o Back up/disaster recovery plan
• SOURCING THE RIGHT PARTNER - http://media.pharmoutsourcing.com/m/30/Article/37498-fig2.jpg
Missing Information/Additional Questions:
Citation and URL: Boucharens, S. (2010). Outsourcing compound inventory trend or real benefits?. Pharmaceutical Outsourcing, Retrieved from
http://www.pharmoutsourcing.com/Featured-Articles/37498-Outsourcing-Compound-Inventory-Trend-or-Real-Benefits/
Page 8 of 8
Purchase answer to see full
attachment